Brefel-Courbon C - Search Results

1

Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.

Moreau C, Delval A, Defebvre L, Dujardin K, Duhamel A, Petyt G, Vuillaume I, Corvol JC, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Sablonniere B, Azulay JP, Tison F, Rascol O, Vidailhet M, Destée A, Bloem BR, Bordet R, Devos D; Parkgait-II study group. Moreau C, et al. Lancet Neurol. 2012 Jul;11(7):589-96. doi: 10.1016/S1474-4422(12)70106-0. Epub 2012 Jun 1. Lancet Neurol. 2012. PMID: 22658702 Clinical Trial.

2

The effectiveness and safety of non-pharmacological intervention for pain management in Parkinson's disease: A systematic review.

Huissoud M, Boussac M, Joineau K, Harroch E, Brefel-Courbon C, Descamps E. Huissoud M, et al. Rev Neurol (Paris). 2024 Oct;180(8):715-735. doi: 10.1016/j.neurol.2023.04.010. Epub 2023 Oct 11. Rev Neurol (Paris). 2024. PMID: 37833205

3

[Parkinson "plus"].

Fabre N, Brefel-Courbon C, Rascol O. Fabre N, et al. Rev Prat. 1997 May 15;47(10):1077-82. Rev Prat. 1997. PMID: 9208670 French.

4

Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy.

Rascol O, Sieradzan K, Peyro-Saint-Paul H, Thalamas C, Brefel-Courbon C, Senard JM, Ladure P, Montastruc JL, Lees A. Rascol O, et al. Mov Disord. 1998 Jul;13(4):673-6. doi: 10.1002/mds.870130411. Mov Disord. 1998. PMID: 9686773 Clinical Trial.

5

Fluoxetine in orthostatic hypotension of Parkinson's disease: a clinical and experimental pilot study.

Montastruc JL, Pelat M, Verwaerde P, Brefel-Courbon C, Tran MA, Blin O, Rascol O, Senard JM. Montastruc JL, et al. Fundam Clin Pharmacol. 1998;12(4):398-402. doi: 10.1111/j.1472-8206.1998.tb00963.x. Fundam Clin Pharmacol. 1998. PMID: 9711461 Clinical Trial.

6

[Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].

Rascol O, Brefel-Courbon C, Blin O. Rascol O, et al. Therapie. 1998 Jan-Feb;53(1):43-8. Therapie. 1998. PMID: 9773099 French.

7

Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.

Rascol O, Brefel-Courbon C, Descombes S, Montastruc JL. Rascol O, et al. Adv Neurol. 1999;80:485-90. Adv Neurol. 1999. PMID: 10410760 Review. No abstract available.

8

Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease.

Thalamas C, Taylor A, Brefel-Courbon C, Eagle S, Fitzpatrick K, Rascol O. Thalamas C, et al. Eur J Clin Pharmacol. 1999 Jun;55(4):299-303. doi: 10.1007/s002280050632. Eur J Clin Pharmacol. 1999. PMID: 10424323 Clinical Trial.

9

Amitriptyline treatment in chronic drug-induced headache: a double-blind comparative pilot study.

Descombes S, Brefel-Courbon C, Thalamas C, Albucher JF, Rascol O, Montastruc JL, Senard JM. Descombes S, et al. Headache. 2001 Feb;41(2):178-82. doi: 10.1046/j.1526-4610.2001.111006178.x. Headache. 2001. PMID: 11251703 Clinical Trial.

10

The pharmacologic treatment of gait ignition failure.

Rascol O, Fabre N, Brefel-Courbon C, Montastruc JL. Rascol O, et al. Adv Neurol. 2001;87:255-64. Adv Neurol. 2001. PMID: 11347230 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

129 results

Search Page

Filters